Skip to content
rejo
Request access
☰
How it worksProductIndustriesInsightsSecuritySign in
Living thesis · Neutral · horizon 2028-04-13

Oracle Cloud Infra to Fall Short of 35% Sustained Growth

Will Oracle's cloud infrastructure revenue (or RPO) grow at least 35% YoY over the next 12-18 months, driven by sustained hyperscaler/AI customer capex flows and GPU leasing demand?

0%8%15%
Probability when written (black), then after each evidence update: green raised it, red lowered it. Fixed arithmetic; each step cites the claim that moved it.

Pillars

What has to be true. Each is updated on its own evidence.

  • 65%
    Oracle's total and cloud revenue growth does not re-accelerate above 35% YoY despite high capex
  • 55%
    Hyperscaler/AI capex flows and GPU leasing demand (exemplified by Tencent) remain sustained but do not overcome pricing and demand risks flagged by suppliers
  • 70%
    Recent GPU rental price increases and elevated capex intensity fail to drive sequential revenue momentum above low-single-digit levels

Kill facts

Stated in advance. If one fires on a filing or a print, the thesis is flagged.

  • Oracle reports cloud infrastructure or total revenue growth at or above 35% YoY in upcoming quartersopen
  • Oracle's capex intensity drops sharply, signaling reduced investment in AI/cloud capacityopen
  • Deferred revenue or RPO shows no material uplift from AI leasing deals like Tencentopen
  • NVDA or hyperscaler commentary confirms lower AI compute demand or pricing pressure materializingopen
  • GPU rental prices reverse the recent 12-17% gains and decline materiallyopen
  • Oracle's sequential revenue growth remains below 5% for multiple quartersopen

Evidence updates

Every revision, in order, with the claim that caused it.

  1. 2026-10-21▼Oracle and AstraZeneca are using AI to accelerate clinical trial recruitment and patient care.· Oracle news10%
  2. 2026-10-21▼Oracle and AstraZeneca are using AI to accelerate clinical trial recruitment and patient care.· Oracle news7%
  3. 2026-10-21▲Oracle and AstraZeneca are using AI to accelerate clinical trial recruitment and patient care.· Oracle news10%
  4. 2026-10-21▼Oracle and AstraZeneca are using AI to accelerate clinical trial recruitment and patient care.· Oracle news7%
  5. 2026-10-21▼Oracle and AstraZeneca are using AI to accelerate clinical trial recruitment and patient care.· Oracle news2%
  6. 2026-10-21▼Oracle and AstraZeneca partnership applies AI specifically to speed up clinical trial recruitment.· Oracle news2%
  7. 2026-10-21▼Oracle and AstraZeneca partnership applies AI specifically to speed up clinical trial recruitment.· Oracle news2%
  8. 2026-10-21▲Oracle and AstraZeneca partnership applies AI specifically to speed up clinical trial recruitment.· Oracle news3%
  9. 2026-10-21▼Oracle and AstraZeneca partnership applies AI specifically to speed up clinical trial recruitment.· Oracle news2%
  10. 2026-10-21▼Oracle and AstraZeneca partnership applies AI specifically to speed up clinical trial recruitment.· Oracle news2%

Strongest cited claims

  • New 10-Q risk-factor language at NVDA: To support our operations and growth, we commit capital to secure supply and capacity, obtain cloud services, and lease data center capacity.

    SEC filing diff (rejo) · 2026-08-26

  • New 10-Q risk-factor language at AVGO: In addition, unfavorable or volatile economic conditions or credit markets could adversely affect the ability of our customers and other AI infrastructure partic

    SEC filing diff (rejo) · 2026-09-10

  • Oracle reported deferred revenue of $14.69B at 2026-08-31.

    SEC XBRL financials (rejo) · 2026-09-11

  • New 10-K risk-factor language at NVDA: The availability of data centers, energy, and capital to support the buildout of NVIDIA AI infrastructure by our customers and partners is crucial, and any short

    SEC filing diff (rejo) · 2026-02-25

  • New 10-Q risk-factor language at NVDA: We may earn a share of revenue generated by sales of the supported capacity, but lower-than-expected AI compute demand or pricing may reduce the revenue we recei

    SEC filing diff (rejo) · 2026-08-26

  • Oracle year-over-year revenue growth was +29.6% in the quarter ended 2026-08-31 (FY2026 Q1).

    SEC XBRL financials (rejo) · 2026-09-11

  • Oracle capex as a share of revenue was 147.3% in the quarter ended 2026-08-31 (FY2026 Q1).

    SEC XBRL financials (rejo) · 2026-09-11

  • Oracle sequential revenue growth was +0.8% in the quarter ended 2026-08-31 (FY2026 Q1).

    SEC XBRL financials (rejo) · 2026-09-11

Snapshot as of 2026-10-23. Drafted by rejo from cited evidence; shown as an example of the product. Not investment advice.

More example theses
Request access →